GLP-1 supply normalisation is shifting the prescribing decision back to clinical fit
Manufacturing capacity for the GLP-1 class has substantially normalised after two years of supply constraint. The prescribing decision is moving back from availability-driven to clinical-fit-driven, and the commercial dynamics are shifting accordingly.
Reading the signal
Semaglutide, tirzepatide and the broader GLP-1 receptor agonist class faced acute supply constraints from 2023 through into 2025 driven by demand outstripping manufacturing capacity. Capacity investment across the major sponsors has eased the constraint materially through 2025 and into 2026.
The prescribing implications of supply normalisation are visible in real-world data:
- Initiation rates have stabilised at higher absolute levels than pre-shortage
- Switching between GLP-1 assets is more common than during the shortage (when switching was constrained by what was available)
- The first-line GLP-1 asset choice is increasingly driven by the cardiovascular outcomes evidence base, the weight-loss magnitude, and the dosing-frequency profile rather than by availability
Differentiation between assets is the commercial story now. The cardiovascular outcomes data (semaglutide CV outcomes trials, tirzepatide cardiovascular outcomes data as it accumulates) is reshaping the cardiovascular-driven first-line decision. The obesity-only first-line decision is more contested and is increasingly driven by weight-loss magnitude and tolerability profile.
Commercial implications
For sponsors with GLP-1 assets in commercial life or in development:
- The differentiation axes are now active. Cardiovascular outcomes data, weight-loss magnitude, dosing frequency, route of administration (oral versus injection), and combination indication breadth are decisive in a way they were not during the shortage.
- Pricing dynamics are shifting. Supply-constrained pricing power is unwinding. Net pricing is normalising at lower levels in some markets, with implications for revenue trajectories that the supply-constrained period obscured.
- The next-generation pipeline matters more. Triple agonists, oral GLP-1, and adjacent obesity-pipeline mechanisms have to compete in the normalised environment, not the supply-constrained one.
What we are watching
- Net pricing data across the major markets and the rate of normalisation
- Cardiovascular outcomes trial readouts for the second-generation GLP-1 and dual-agonist assets
- The oral GLP-1 commercial story and how patient preference shifts as the oral route becomes available alongside the injection route
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.